1			
2			
3			
4	Copy number variants differ in frequer	icy across genetic ancestry groups	
5			
6	Laura M. Schultz ^{1,2,*} , Alexys Knighton ³ , Guillaume	Huguet ⁴ , Zohra Saci ⁴ , Martineau Jean-Louis ⁴ ,	
7	Josephine Mollon ⁵ , Emma E.M. Knowles ⁵ , David	C. Glahn ⁵ , Sébastien Jacquemont ^{4,6} , Laura	
8	Almasy ^{7,}	1,2*	
9			
10	¹ Department of Biomedical and Health Informatics, Children'	s Hospital of Philadelphia, Philadelphia, PA, USA	
11	² Lifespan Brain Institute, Children's Hospital of Philadelphia a	nd the University of Pennsylvania, Philadelphia, PA,	
12	USA ³ School of Arts and Sciences, University of Dennsylvania, Dhild	adalahia DA LICA	
15 14	⁴ CHILSainte-Justine Montréal OC Canada	idelphia, PA, USA	
15	⁵ Department of Psychiatry, Boston Children's Hospital, Harva	rd Medical School, Boston, MA, USA	
16	⁶ Department of Pediatrics, Université de Montréal, Montréal	, QC, Canada	
17	⁷ Department of Genetics, Perelman School of Medicine, Univ	ersity of Pennsylvania, Philadelphia, PA, USA	
18			
19			
20			
21	*Corresponding Authors:		
22		Laura M. Calculta	
23 24	Laura Almasy	Laura M. Schultz	
24 25	3615 Civic Center Blvd	3615 Civic Center Blvd	
26	Philadelphia PA 19104 USA	Philadelphia PA 19104 USA	
27	phone: 215-590-3031	phone: 215-590-3244	
28	Email: almasyl@chop.edu	Email: schultzl1@chop.edu	
29			
30			
31	Abstract		
32			
33	Copy number variants (CNVs), which are duplicated	l or deleted genomic segments larger than	
34	1000 base pairs ¹ , have been implicated in a variety	of neuropsychiatric and cognitive	
35	phenotypes ²⁻⁴ . In the first large-scale of examination	n of genome-wide CNV frequencies across	
36	ancestry groups, we found that deleterious CNVs a	re less prevalent in non-European ancestry	
37	groups than they are in European ancestry groups	of both the UK Biobank (UKBB) and a US	
38	replication cohort (SPARK). We also identified spec	cific recurrent CNVs that consistently differ in	
39	frequency across ancestry groups in both the UKBB and SPARK. These ancestry-related		
40	differences in CNV prevalence present in both an unselected community population and a		
41	tamily cohort enriched with individuals diagnosed with autism spectrum disorder (ASD) strongly		
42	suggest that genetic ancestry should be considered when probing associations between CNVs		
43	and health outcomes.		
44			
45			
46			

47	CNVs are associated with a wide range of human complex traits ⁵⁻⁷ and diseases ⁸⁻¹¹ . They
48	are especially well-studied in neurodevelopmental ¹²⁻¹⁵ and psychiatric disorders ^{4,15-18} , most
49	notably ASD ¹⁹⁻²² and schizophrenia ²³⁻²⁵ . Unfortunately, most CNV association studies have been
50	limited to European (EUR) ancestry groups ^{2,5-9 11} or pooled across ancestry groups ^{10,13-15,17,19-}
51	^{21,23} . While some studies have characterized CNVs in African (AFR) ²⁶⁻²⁹ and other non-EUR
52	ancestry groups ^{15,30-32} , efforts to compare CNV frequencies across ancestry groups have been
53	inconclusive due to limited sample sizes. ^{14,33-40} Since genetic variation among human
54	populations ^{41,42} contributes to differential disease risk ⁴³⁻⁴⁶ , immune response ^{47,48} , and
55	pharmacogenomics ^{49,50} , it is plausible that ancestry-related differences in CNV frequency could
56	impact precision medicine. Hence, we took advantage of previously overlooked diversity within
57	the UKBB to compare CNV frequency across four genetic ancestry groups: individuals with
58	inferred EUR (<i>n</i> = 51,334), South Asian (SAS; <i>n</i> = 8,848), or AFR (<i>n</i> = 8,447) ancestry plus a
59	subset of EUR-ancestry individuals who self-identified as "white British" (WB; <i>n</i> = 385,636)
60	(Extended Data Fig. 1). Even though the SAS and AFR groups each represent about 2% of the
61	UKBB, they are orders of magnitude larger than the non-EUR groups included in previous CNV
62	studies.
63	When we considered all autosomal CNVs consisting of at least 50,000 base pairs, we
64	found that the carrier frequency was generally similar across ancestry groups. Nonetheless,

65 there were more deletion (DEL) carriers in the EUR and SAS groups and duplication (DUP)

66 carriers in the WB group than expected given the group size (Fig. 1a). For all ancestry groups,

67 DEL carriers were more common than DUP carriers.

68 Given that CNVs have a range of effect sizes, as judged by their association with health 69 outcomes or by their degree of evolutionary constraint, we considered several subsets of CNV 70 carriers. First, we limited our analyses to carriers of a pre-selected set of recurrent CNVs with 71 common breakpoints that were previously observed in multiple individuals and found to be 72 associated with neuropsychiatric phenotypes (Supplementary Table 1). We observed 50 73 unique recurrent deletions (Supplementary Table 2) and 60 unique recurrent duplications 74 (Supplementary Table 3) at these loci in the UKBB. Of the 110 unique recurrent CNVs observed 75 in the combined sample, 106 were present in the WB. The 4 CNVs not observed in the WB 76 group were present in the EUR group, where we observed 77 unique recurrent CNVs. The 40 77 unique recurrent CNVs observed in the AFR group and the 36 in the SAS group were subsets of 78 those observed in the WB and EUR groups; none of the 110 recurrent CNVs were unique to the 79 non-EUR ancestry groups in the UKBB. There were significantly fewer AFR-ancestry recurrent 80 DEL and DUP carriers than expected under the null hypothesis that recurrent CNV carrier 81 frequency is independent of ancestry group (Fig. 1b). 82 Next, we filtered CNV carriers using the loss-of-function observed/expected upper bound fraction (LOEUF)⁵¹ constraint metric. When we limited our analyses to carriers of CNVs 83 84 with constraint scores equivalent to disruption of at least two predicted loss-intolerant genes 85 (i.e., total $1/LOEUF \ge 5.7$ summed across the genes within the CNVs carried by an individual), 86 ancestry-related differences persist and become even stronger. Consistent with previous evidence that DELs in coding sequences are under stronger purifying selection than DUPs⁵², the 87

89 ancestry groups. The deleterious DEL carrier frequency for WB individuals was nearly twice

88

3

burden-filtered carrier frequency for DELs was substantially lower than that for DUPs for all four

that of AFR or SAS individuals, both when we filtered by 1/LOEUF summed across all CNVs (Fig.
1c) and when we limited the summation to recurrent CNVs (Fig. 1d). Likewise, carriers of
deleterious DUPs were more prevalent in the WB group and less prevalent in the AFR group
than expected. We obtained similar results when we excluded all individuals related at the
third-degree or closer (Extended Data Fig. 2; Supplementary Table 4).

95 We also examined the prevalence of individual recurrent CNVs. To maximize power, we 96 limited our analysis to the 11 recurrent CNVs (5 DELs and 6 DUPs) that each had a total of 275 97 or more observations across the four ancestry groups. We found ancestry-related differences 98 in the prevalence of 6 of these CNVs (Fig. 2), with some CNVs being more prevalent in WB 99 individuals but others occurring at higher rates in the AFR and SAS groups. While there were 100 some related individuals among the carriers of some of the CNVs, the pattern of frequency 101 differences was essentially unchanged when we excluded all individuals with third-degree or 102 closer relatives from the dataset (Extended Data Fig. 3; Supplementary Table 4). Hence, the 103 observed differences cannot be explained by related individuals carrying the same CNVs. 104 Ascertainment bias is another potential explanation for the lower rate of deleterious 105 CNVs in some ancestry groups within the UKBB. Immigrants may be less likely to participate in 106 the UKBB, especially if they are carriers of deleterious CNVs. While EUR, AFR, and SAS 107 individuals were more likely to have been born outside the UK or Ireland than WB individuals, 108 the proportions of SAS and AFR individuals who were immigrants did not significantly differ for 109 recurrent CNV carriers compared to non-carriers (Extended Data Fig. 4), suggesting that 110 differential immigration rates cannot explain the differences in CNV prevalence across ancestry 111 groups.

112 Demographic differences between the UKBB ancestry groups could also contribute to 113 the observed differences in CNV prevalence. Individuals in the SAS and AFR ancestry groups 114 tend to be younger than those in the WB and EUR groups, and the female-to-male ratios 115 differed across the ancestry groups (Supplementary Tables 5-6). Furthermore, median 116 Townsend deprivation index scores suggest that there are socioeconomic differences that could 117 be associated with ancestry, sex, and recurrent CNV carrier status (Supplementary Table 7). 118 We used propensity score matching to balance the sample sizes and control for the potentially 119 confounding effects of these variables on CNV carrier rates by down-sampling the WB group to 120 create two subgroups matched to the AFR and SAS groups (Extended Data Fig. 5; 121 **Supplementary Tables 8-9**). The AFR-ancestry group had significantly lower odds of carrying 122 both unfiltered and 1/LOEUF-filtered recurrent DELs and DUPs than its matched WB group (all 123 two-sided Fisher's exact test *p*-values < .0000005; **Fig. 3**). Indeed, the matched comparisons 124 yielded more pronounced differences than the unmatched ones despite having smaller sample 125 sizes. In contrast, differences between the SAS and matched WB group were somewhat 126 attenuated. Nonetheless, the SAS group showed significantly lower odds of carrying 1/LOEUF-127 filtered recurrent DELs when compared to its matched WB group (p < .00001). 128 We also used the matched datasets to compare the odds of carrying our 11 recurrent 129 CNVs of interest (Fig. 4) and found that most of the observed ancestry-related differences in 130 CNV prevalence remained significant. Using two-sided Fisher's exact tests of the carrier ORs, 131 we found that the AFR group had significantly lower odds of carrying 2q13 NPHP1 DEL, CRYL1 132 DEL, 15q11.2 DEL, 15q13.3 BP4.5-BP5 CHRNA7 DUP, 16p13.11 DUP, and 22q11.2 proximal (with 133 LCR-A) DUP as well as higher odds of carrying 2q13 NPHP1 DUP compared to its matched WB

134 group. The SAS group also had significantly lower odds of carrying 2q13 NPHP1 DEL, CRYL1 DEL, 135 15q11.2 DEL, 15q13.3 BP4.5-BP5 CHRNA7 DUP, and 22q11.2 proximal (with LCR-A) DUP and 136 higher odds of carrying 2g13 NPHP1 DUP compared to its matched WB group. Additionally, the 137 SAS group had higher odds of carrying ZNF92 DEL and 15q11.2 DUP compared to its matched 138 WB group. 139 Finally, we replicated our study using SPARK, a younger United States cohort enriched 140 with individuals diagnosed with ASD and ID (Supplementary Tables 10-12). We observed 51 141 unique recurrent deletions (Supplementary Table 13) and 51 unique recurrent duplications 142 (Supplementary Table 14) across the three largest inferred ancestry groups (Extended Data Fig. 143 6) comprised of 46,869 EUR, 7,870 admixed American (AMR), and 3,680 AFR individuals. We 144 used propensity score matching to balance the sample sizes and control for potentially 145 confounding effects of ASD and ID status, age, and sex on recurrent CNV carrier rates by down-146 sampling the EUR group to create two subgroups matched to the AFR and AMR groups 147 (Extended Data Fig. 7; Supplementary Tables 15-16). Replicating our UKBB results, we found 148 that the SPARK AFR group had significantly lower odds of carrying both unfiltered and 1/LOEUF-149 filtered recurrent DELs and DUPs than its matched EUR group (all two-sided Fisher's exact test 150 *p*-values < .005; **Fig. 5**). The AMR group had significantly lower odds of carrying both unfiltered 151 and 1/LOEUF filtered recurrent DUPs (two-sided Fisher's exact test p-values < .005; Fig. 5). 152 We also used the matched datasets to compare the odds of carrying the same 11 153 recurrent CNVs we analyzed for the UKBB along with two additional recurrent CNVs that had at 154 least 75 copies each in SPARK despite not meeting our inclusion criteria for the UKBB (Fig. 6). 155 Replicating our UKBB results, the SPARK AFR group showed significant differences for 2q13

156	NPHP1 DEL, 15q11 DEL, 2q13 NPHP1 DUP, 15q13.3 BP4.5-BP5 CHRNA7 DUP, and 16p13.11 DUP
157	carrier odds relative to its matched EUR group (two-sided Fisher's exact test <i>p</i> -values < .05).
158	Additionally, the SPARK AFR group had significantly lower odds of carrying NRXN1 DEL and
159	higher odds of carrying 16p12.1 DEL relative to its matched EUR group, and the SPARK AMR
160	group had significantly lower odds of carrying NRXN1 DEL, 15q11.2 DEL, and 1q21 TAR DUP
161	relative to its matched EUR group (two-sided Fisher's exact test <i>p</i> -values < .05).
162	One potential explanation for the difference in prevalence of specific CNVs across
163	ancestry groups is that population variation in the flanking sequence may affect the probability
164	of deletions and duplications in a region. For example, chromosomal regions with polymorphic
165	inversions have been shown to be enriched for recurrent CNVs associated with developmental
166	delay and neuropsychiatric disorders.53
167	We demonstrated that ancestry-related differences in CNV carrier prevalence are
168	present in both unselected community populations (UKBB) and cohorts enriched with ASD-
169	diagnosed individuals (SPARK). We replicated the observed differences between the AFR and
170	WB cohorts in the UKBB by comparing the AFR and EUR cohorts in SPARK, which is notable
171	given the ascertainment differences, differing genotyping platforms (Methods), and presumed
172	genetic differences between the homogeneous WB subset of the UKBB and a EUR-ancestry
173	cohort from the United States ⁵⁴ . Furthermore, SAS (UKBB) and AMR (SPARK) ancestry groups
174	also exhibited unique patterns of CNV prevalence, demonstrating that differences in CNV
175	carrier prevalence cannot be generalized as "EUR vs. non-EUR" differences.
176	Given that African populations have been shown to have greater genetic diversity ⁵⁵ , the
177	finding of fewer rare CNVs in the AFR groups of UKBB and SPARK is somewhat surprising. One

possible explanation for our ancestry-divergent results could be the "Euro-centric" focus of 178 179 previous studies of genetic variants.⁴³ To focus on deleterious CNVs, we limited some of our 180 analyses to recurrent CNVs that had been previously implicated in neuropsychiatric disorders 181 and/or filtered our results based on the LOEUF metric. Our targeted recurrent CNVs were 182 originally identified in cohorts dominated by EUR-ancestry individuals, so it is conceivable that 183 there are as-yet-undiscovered CNVs with medical relevance that are more common in other 184 ancestry groups. Also, the LOEUF constraint metric was derived from the gnomAD v2 reference 185 database, which includes sequences from 64,603 individuals from European populations and 186 only 12,487 individuals from African (or African-American) and 15,308 individuals from South Asian populations⁵¹. We expect that the discovery of additional recurrent CNVs, especially 187 those smaller than 50 kb, will be facilitated by the increasing availability of long-read whole 188 189 genome sequence data collected from diverse populations, such as All of Us^{40,56}. In any case, it is likely that differing linkage disequilibrium patterns³⁵ and flanking sequences⁵⁷ also 190 191 contributed to the ancestry-related differences in CNV frequency that we found. Future CNV 192 studies utilizing long-read sequences should clarify the extent to which polymorphic differences 193 in the flanking sequence across populations contribute to the observed differences in CNV 194 frequency. 195 These findings are limited by the sample sizes of the AFR, SAS, and AMR ancestry groups

in the UKBB and SPARK, which are much smaller than those of the WB and EUR ancestry
groups. Larger CNV studies of diverse samples are needed. Additional limitations include our
focus on only CNVs over 50 kilobases, a by-product of using genotype array data to call CNVs,
and the choice of LOEUF as a metric of the deleteriousness of a CNV. Given that LOEUF is

200	focused on coding genes, non-coding CNVs that impact important regulatory elements may
201	have been missed in our filtered set of deleterious CNVs with $1/LOEUF \ge 5.7$. Strengths of the
202	study include the use of propensity score matching to address potential sources of bias and the
203	consistency of results across samples with very different demographic profiles and
204	ascertainment schemes.
205	Although classifying individuals into continental ancestry groups imposes discrete
206	categories onto what is actually a continuum of human genetic variation ^{58,59} , it has nonetheless
207	been a useful approach for considering the potential effects of population structure on
208	genome-wide association analyses ^{60,61} . We recommend that CNV association studies also be
209	adjusted for population structure, ideally in a quantitative way that reflects the continuous
210	spectrum of genetic variation, to limit the risk of spurious discoveries.
211 212 213	Methods
213	Cohorts
215 216	We obtained de-identified genotype and phenotype data for the UK Biobank ⁶² (UKBB;
217	application number 40980), a prospective population-based cohort of approximately 500,000
218	United Kingdom residents who were 40-69 years old when they were recruited between 2006
219	and 2010.
220	We replicated our primary results using data from Simons Powering Autism Research for
221	Knowledge (SPARK) ⁶³ , a United States cohort of children and dependent adults diagnosed with
222	autism spectrum disorder (ASD) and their families.
223	

224 Genotyping and CNV Calling

225 UKBB DNA samples were extracted from blood and genotyped on either the UK BILEVE 226 Axiom Array (n = 49,950) or the UK Biobank Axiom Array (n = 438,427) by Affymetrix. We 227 selected 733,256 probes shared by the two arrays when mapped to hg19. Intensity data were 228 used to call CNVs for the 459,855 individuals who remained after excluding 28,522 samples that 229 failed to meet our quality control (QC) standards of genotype call rate > 0.95, |waviness factor| 230 < 0.05, log *R* ratio SD < 0.35, and B allele frequency SD < 0.08. 231 SPARK DNA samples were extracted from saliva and genotyped on four different 232 Illumina Infinium arrays: Global Screening Array (GSA)-24 v1.0 (n = 26,868), GSA-24 v2.0 (n = 26,868) 233 32,397), CoreExome-24 v1.1 (n = 1,382), and CoreExome-24 v1.3 (n = 6,024). When mapped to 234 hg19, the two GSA arrays had 617,394 autosomal SNPs in common with each other and 235 218,457 SNPs in common with the 733,256 probes used to call CNVs for the UKBB, and the 236 CoreExome arrays had 514,277 autosomal SNPs in common with each other and 98,648 in 237 common with the UKBB probes. The four Illumina arrays had a total of 514,273 autosomal 238 SNPs in common. Intensity data were used to call CNVs for the 65,425 individuals who 239 remained after excluding the samples that failed to meet the same QC standards listed above 240 for the UKBB. CNVs were called in parallel by PennCNV⁶⁴ and QuantiSNP⁶⁵ using our previously 241 published pipeline^{66,67}. Both algorithms combine normalized intensity data with log R ratio 242 243 (LRR) and B allele frequency (BAF) into hidden Markov models to detect CNVs that meet the 244 following criteria: coverage \geq 3 consecutive probes, size \geq 1 kB, and confidence score \geq 15. CNVs jointly detected by both algorithms were merged using CNVision⁶⁸, and a CNV inheritance 245

algorithm was used to concatenate adjacent duplications (DUPs) or deletions (DELs) separated
by a gap no larger than 150 kB. Only CNVs meeting the following criteria were selected for
further analyses: confidence score ≥ 30 for at least one detection algorithm; size ≥ 50 kB;
unambiguous type (DUP or DEL); and less than 50% overlap with segmental duplicates, HLA
regions, or centromeric regions.

251

252 Genetic Ancestry Inference

253 Ten principal components (PCs) were computed from the imputed genotypes supplied 254 by the UKBB (Data-Field 22828; v.3) and projected onto the 1000 Genomes PC space using KING 255 v2.2.4⁶⁹. Genetic ancestry was inferred from these PCs via a support vector machine algorithm 256 using the e1071 R package⁷⁰. Additionally, a subset of 385,636 European-ancestry individuals 257 who self-identified as being "white British" (Data-Field 22006) was defined; the white British 258 (WB) subgroup formed a tight subcluster within the European-ancestry cluster on the PC2 vs. 259 PC1 plot (Extended Data Fig. 1a). All subsequent analyses were limited to these WB individuals 260 in addition to 51,334 other European (EUR), 8,848 South Asian (SAS), and 8,447 African (AFR) 261 ancestry individuals. While KING called the ancestry whenever the posterior probability was at 262 least 65%, the majority (93.2%) of the calls were made with posterior probability \geq 90% 263 (Extended Data Fig. 1b), suggesting that admixture was limited. Nonetheless, we recognize 264 that genetic ancestry is continuous and does not equate with self-identified ethnicity (Data-265 Field 21000; Extended Data Fig. 1c). 266 Genetic ancestry was inferred using this same approach for the SPARK samples included

in the iWESv2 or the WGS1-3 data releases. After excluding any individuals who were missing

	•				
268	trom the individuals	registration tile su	ipplied with the lub	v 2023 SPARK V10 release	. we limited
200		regioti actori ine oc			,

- all subsequent analyses to 46,869 EUR, 7,870 admixed American (AMR) and 3,680 AFR ancestry
- 270 individuals (Extended Data Fig. 6; Supplementary Tables 10-12).
- 271

272 CNV Annotation

- 273 CNVs were annotated in GRCh37 using GENCODE Release 35
- 274 (https://www.gencodegenes.org/human/release 35lift37.html) and Ensembl
- 275 (https://grch37.ensembl.org/index.html). Genes that were fully contained within a CNV were
- identified, and the inverse loss-of-function observed/expected upper-bound fraction (1/LOEUF)

from gnomAD (version 2.1.1)⁵¹ was summed across all full genes contained within all CNVs

- 278 detected for each study participant. A CNV was classified as a "recurrent CNV" if it met defining
- 279 criteria for any of a pre-selected set of recurrent and single-gene autosomal CNVs that have
- 280 been previously associated with neurodevelopmental or neuropsychiatric phenotypes
- 281 (Supplementary Table 1). Partial genes were also included in the 1/LOEUF calculations for
- these recurrent CNVs. We use "all CNVs" to refer to these pre-selected recurrent CNVs plus all
- other CNVs over 50kB. An individual's total 1/LOEUF was summed across full genes for all CNVs
- as well as any partial genes that were included in the pre-defined recurrent CNVs, whereas total
- 285 1/LOEUF calculations made for an individual's recurrent CNVs were limited to the full and
- 286 partial genes present within these pre-defined recurrent and single-gene CNVs. We observed
- 50 unique recurrent DELs (**Supplementary Table 2**) and 60 unique recurrent DUPs
- 288 (Supplementary Table 3) across our four defined UKBB ancestry groups. For the SPARK
- replication, we limited our analyses to the 51 unique recurrent DELs (**Supplementary Table 13**)

and 51 unique recurrent DUPs (Supplementary Table 14) we observed across the three defined
SPARK ancestry groups.

292

293 Carrier Prevalence

294 We calculated carrier prevalence as the number of individuals within a given ancestry 295 group who carried at least one of a given class of CNV divided by the total number of individuals 296 in that ancestry group. For the UKBB, prevalence calculations were made for the following 297 classes: (1) carriers of at least one DEL > 50kB, (2) carriers of at least one DUP > 50kB, (3) 298 carriers of at least one of 50 pre-defined recurrent DELs (Supplementary Table 2), (4) carriers 299 of at least one of 60 pre-defined recurrent DUPs (Supplementary Table 3), (5) carriers of at least one DEL with a total 1/LOEUF of at least 5.7 summed across all full genes included in all 300 301 DELs plus any partial genes included in any of 50 pre-defined recurrent DELs, (6) carriers of at 302 least one DUP with a total 1/LOEUF of at least 5.7 summed across all full genes included in all 303 DUPs plus any partial genes included in any of 60 pre-defined recurrent DUPs, (7) carriers of at 304 least one of the 50 pre-selected recurrent DELs with a total 1/LOEUF of at least 5.7 summed 305 across full and partial genes included in those recurrent DELs, and (8) carriers of at least one of 306 the 60 pre-selected recurrent DUPs with a total 1/LOEUF of at least 5.7 summed across full and 307 partial genes included in those recurrent DUPs. Prevalence calculations for the SPARK 308 replication were limited to (1) carriers of at least one of 51 pre-defined recurrent DELs 309 (Supplementary Table 13), (2) carriers of at least one of 51 pre-defined recurrent DUPs (Supplementary Table 14), (3) carriers of at least one of the 51 pre-selected recurrent DELs 310 311 with a total 1/LOEUF of at least 5.7 summed across full and partial genes included in those

312	recurrent DELs, and (4) carriers of at least one of the 51 pre-selected recurrent DUPs with a
313	total 1/LOEUF of at least 5.7 summed across full and partial genes included in those recurrent
314	DUPs. We used a threshold of total 1/LOEUF = 5.7, which corresponds to approximately two
315	intolerant genes, as a means of identifying carriers of deleterious CNVs.
316	We also evaluated ancestral differences in carrier prevalence for 5 individual recurrent
317	DELs (NRXN1, 2q13 NPHP1, ZNF92, CRYL1, and 15q11.2) and 6 individual recurrent DUPs
318	(1q21.1 TAR, 2q13 NPHP1, 15q11.2, 15q13.3 BP4.5-BP5 CHRNA7, 16p13.11, and 22q11.2) in the
319	UKBB. A recurrent CNV was selected for this round of analysis if it had at least 275 total
320	observations in the combined UKBB dataset. We chose this threshold a priori because, under
321	the null hypothesis that CNV carrier prevalence is not associated with ancestry (i.e., they are
322	equally distributed across the ancestry groups), we would expect at least five carriers of each
323	CNV in the AFR and SAS ancestry groups. For the SPARK replication, we analyzed the same
324	eleven recurrent CNVs we selected for analysis for the UKBB along with two additional CNVs,
325	16p11.2 proximal DEL and 16p12.1 DEL, that each had more than 75 observations in SPARK
326	(since we would expect at least 5 observations of these CNVs in the AFR and AMR groups under
327	our null hypothesis) but did not meet our inclusion criteria for the UKBB.
328	

329 Sensitivity Analysis

We repeated our carrier prevalence calculations after excluding all individuals who had a least one third-degree or closer relative in the full UKBB dataset. Since these exclusions reduced our sample sizes (**Supplementary Tables 4-6**) without altering our primary findings

(Supplementary Table 4; Extended Data Figs. 2 and 3), all subsequent UKBB analyses were run
using only the full dataset.

335

336 Environmental Phenotypes

337 Next, we explored whether the observed ancestry-related differences in CNV carrier 338 prevalence could be explained by ascertainment differences. Hypothesizing that recent 339 immigrants may be genetically fitter and, hence, less likely to possess recurrent CNVs, we 340 compared the birth countries (Data-field 1647) of the recurrent CNV carriers within each 341 ancestry group to those of the non-carriers (Extended Data Fig. 4) and quantified the difference 342 for each ancestry group with the ratio of the odds of being a recurrent CNV carrier when born 343 within the UK or Ireland to the odds when born elsewhere. Individuals born in England, Wales, 344 Scotland, Northern Ireland, or the Republic of Ireland were coded as being born within the UK 345 or Ireland. Individuals who indicated they did not know their place of birth or preferred not to answer were excluded from this analysis. 346 347 We also considered whether Townsend Deprivation Index (TDI; Data-field 189), a proxy for socioeconomic status, differed between ancestry groups or based on recurrent CNV carrier 348

349 status (**Supplementary Table 7**). TDI scores were assigned to each subject based on the postal

code where they resided immediately prior to enrolling in the UKBB. Note that larger, more

positive TDI scores are associated with a higher degree of deprivation.

352

350

351

353 Propensity Score Matching

354 Given the unbalanced sample sizes, sex ratios, age distributions, and TDI distributions 355 across the four ancestry groups in the UKBB (Supplementary Tables 5 and 7), we employed 356 propensity-score matching to control for these potentially confounding variables before 357 running another round of analyses. After excluding individuals who were missing age and/or 358 TDI data, we used the MatchIt⁷¹ R package to make two sets of 1:1 nearest neighbor matches 359 without replacement by estimating a propensity score via logistic regression of ancestry on TDI, 360 age, and sex (Extended Data Fig. 5). One WB subgroup (WB-AFR; n = 8,425) was matched to 361 the remaining AFR individuals (n = 8,425), and a second WB subgroup (WB-SAS; n = 8,835) was 362 matched to the remaining SAS individuals (n = 8,835); we did not include the EUR group in this 363 round of analyses. The matching procedure yielded good balance, as evidenced by 364 standardized mean differences and empirical CDF statistics close to zero and variance ratios 365 close to one for both the WB-AFR matches (Supplementary Table 8) and WB-SAS matches 366 (Supplementary Table 9). We used odds ratios (ORs) to quantify the differences in carrier frequency between the 367 matched datasets. Odds were calculated as the number of carriers divided by the number of 368 369 non-carriers within a given group. Then, two sets of ORs were computed by dividing the AFR 370 odds by the WB-AFR odds and the SAS odds by the WB-SAS odds. These ORs were computed 371 for the same four classes of recurrent CNVs and 11 individual recurrent CNVs that were

372 described above.

The SPARK replication dataset also had confounding variables that we controlled using
propensity score matching. Not only do the sex ratios and ages vary substantially between ASD

375 cases and controls and between ancestry groups, but the relative proportions of ASD cases with 376 and without intellectual disability (ID) also differ across the ancestry groups (Supplementary 377 Tables 10 and 12). We distinguished between cases and controls using the *asd* variable from 378 the individuals registration file and assigned ID status to the cases using the 379 derived cog impair variable from the predicted ig experimental file included in the SPARK 380 V10 release. 381 After excluding individuals who were missing age or ID data, we used the Matchlt⁷¹ R 382 package to make two sets of 1:1 nearest neighbor matches without replacement by estimating 383 a propensity score via logistic regression of ancestry on combined ASD/ID status (i.e., control, 384 ASD without ID, or ASD with ID), age, and sex (Extended Data Fig. 7). One EUR subgroup (EUR-385 AFR; n = 3,473) was matched to the remaining AFR individuals (n = 3,473), and a second EUR 386 subgroup (EUR-AMR; n = 7,405) was matched to the remaining AMR individuals (n = 7,405). The 387 matching procedure yielded good balance, as evidenced by standardized mean differences and 388 empirical CDF statistics close to zero and variance ratios close to one for both the EUR-AFR 389 matches (Supplementary Table 15) and EUR-AMR matches (Supplementary Table 16). 390 We used ORs to quantify the differences in carrier frequency between the matched 391 SPARK datasets. Odds were calculated as the number of carriers divided by the number of non-392 carriers within a given group. Then, two sets of ORs were computed by dividing the AFR odds 393 by the EUR-AFR odds and the AMR odds by the EUR-AMR odds. These ORs were computed for

the same four classes of recurrent CNVs and the 13 individual recurrent CNVs that were

395 described above.

396

397 Statistical Analyses

398	R (version 4.2.1) ⁷² was used to run statistical analyses and generate graphical displays.
399	Carrier prevalence differences among the four unmatched UKBB ancestry groups were
400	evaluated for statistical significance using chi-square tests for independence with simulated p-
401	values (2000 iterations). All tests included an additional "none of the above" group (not
402	included in the figures) so that a given observed proportion (i.e., observed count / n) was
403	equivalent to carrier prevalence. Significant differences between expected and observed carrier
404	counts were identified using Benjamini-Hochberg FDR-corrected <i>p</i> -values assigned to the
405	standardized residuals. The ORs for the matched UKBB comparisons (AFR vs. WB-AFR and SAS
406	vs. WB-SAS) and matched SPARK comparisons (AFR vs. EUR-AFR and AMR vs. EUR-AMR) were
407	evaluated using two-sided Fisher's exact test <i>p</i> -values and plotted with their corresponding 95%
408	confidence intervals. We conducted a Mantel-Haenszel test of homogeneity to compare the
409	ancestry-specific birth location ORs for the UKBB, and we used two-sided Fisher's exact tests to
410	evaluate whether the odds of being a recurrent CNV carrier were lower for individuals of given
411	ancestry group who were born outside the UK or Ireland (i.e., immigrants) than they were for
412	those born within the UK or Ireland. We plotted the Mantel-Haenszel pooled OR and ancestry-
413	specific birthplace ORs with their 95% Wald confidence intervals.

414

415 **Data Availability**

- 416
- 417 Raw genotype and phenotype data are available via application to the UK Biobank
- 418 (https://www.ukbiobank.ac.uk/). Approved researchers can obtain the SPARK dataset
- 419 described in this study by applying at <u>https://base.sfari.org</u>.
- 420

421 Code Availability

- 422
- 423 Custom Python code and a detailed description of our CNV calling pipeline is provided at
- 424 https://martineaujeanlouis.github.io/MIND-GENESPARALLELCNV/.
- 425

426 Acknowledgements

- 427 This work used the UK Biobank, a major biomedical database, under application number
- 428 40980 and was funded by the National Institute of Mental Health (NIMH) grant number U01-
- 429 MH119690. We are grateful to all the families in SPARK, the SPARK clinical sites, and SPARK
- 430 staff, and we appreciate obtaining access to phenotypic and genetic data on SFARI Base.

432 Figures and Legends

0.00

DEL

White British

(n = 385, 636)





0.000

South Asian

(n = 8.848)

DEL

African

(n = 8.447)

DUP

434 435

436 Fig. 1: CNV carrier prevalence by ancestry group in the UK Biobank. a. When CNVs are not 437 filtered based on recurrence or burden, deletion (DEL) carrier prevalence is higher than 438 expected for the South Asian ancestry group (SAS), and duplication (DUP) carrier prevalence is 439 lower than expected for the African ancestry group (AFR) (χ^2 = 146.7). **b.** When considering only recurrent CNVs, there were fewer AFR DEL and DUP carriers than expected ($\chi^2 = 48.145$). 440 441 **c.** Filtering instead on burden (total $1/LOEUF \ge 5.7$), there were fewer DEL and DUP carriers 442 than expected for both AFR and SAS ($\chi^2 = 126.89$). **d.** Limiting to carriers of recurrent CNVs with 443 total $1/\text{LOEUF} \ge 5.7$, DEL carrier prevalence was lower than expected for both AFR and SAS, but DUP carrier prevalence was only lower than expected for AFR (χ^2 = 61.397). Plus signs indicate 444 significantly higher than expected carrier prevalence, and minus signs indicate significantly 445 446 lower than expected carrier prevalence. Ancestry-specific carrier prevalence was computed as 447 the number of carriers of at least one DEL (or DUP) divided by the total number of individuals in 448 that ancestry group. Simulated p-values (2000 replicates) were less than .0005 for all four chi-449 square tests of independence. 1/LOEUF, inverse loss-of-function observed/expected upperbound fraction; **FDR-corrected p-value < .005; ***FDR-corrected p-value < .0005. An 450 451 additional category ("Neither") that was included in each chi-square test is not shown in the bar 452 charts. 453 454

Other European

(n = 51.334)

DUP





457 Fig. 2: Prevalence of individual recurrent CNVs across ancestry groups in the UK Biobank.

458 There were significant differences between expected and observed counts for 6 out of the 11

459 recurrent CNVs selected for analysis, $\chi^2 = 425.3$, simulated *p*-value < .0005 (2000 replicates).

460 Carrier prevalence was calculated as the number of carriers of a given recurrent CNV divided by

the total number of individuals in that ancestry group. Plus and minus signs indicate that the

standardized residuals were statistically significantly higher or lower than zero, respectively,
after FDR correction. *FDR-corrected *p*-value < .05; **FDR-corrected *p*-value < .005; ***FDR-

464 corrected *p*-value < .0005. An additional category ("none of the above") that was included in 465 the chi-square test is not shown in the bar chart.

466

- 468
- 469
- 470



471

472 Fig. 3: Odds of carrying deleterious CNVs in AFR- and SAS-ancestry individuals compared to

473 WB individuals in the UK Biobank after propensity-score matching on Townsend deprivation

474 **index, age, and sex.** Odds were computed as the number of carriers divided by the number of

475 non-carriers of a given type of recurrent CNV. Odds ratios (ORs) were computed as AFR odds
476 divided by WB odds (purple dots) or SAS odds divided by WB odds (blue dots) using unmatched

477 (open dots) or matched (filled dots) data. Error bars indicate 95% Fisher confidence limits for

478 the OR computed using matched data, and the *p*-value is for the corresponding two-sided

479 Fisher's exact test for that OR. The red dashed lines indicate the expected OR of 1 (i.e., equal

480 odds). AFR odds were lower than the WB odds at each level of filtering, but SAS odds were not

481 consistently lower than the WB odds. Unmatched odds were calculated using data from

482 385,636 White British (WB), 8,447 African (AFR), and 8,848 South Asian (SAS) individuals.

483

484 485



486







503 Fig. 5: Odds of carrying deleterious CNVs in AFR- and AMR-ancestry individuals compared to 504 505 EUR-individuals in SPARK after propensity-score matching on autism spectrum disorder and intellectual disability status, age, and sex. Odds were computed as the number of carriers 506 507 divided by the number of non-carriers of a given type of recurrent CNV. Odds ratios (ORs) were 508 computed as AFR odds divided by EUR odds (purple dots) or AMR odds divided by WB odds 509 (blue dots) using unmatched (open dots) or matched (filled dots) data. Error bars indicate 95% 510 Fisher confidence limits for the OR computed using matched data, and the p-value is for the 511 corresponding two-sided Fisher's exact test for that OR. The red dashed lines indicate the 512 expected OR of 1 (i.e., equal odds). AFR carrier odds were lower than the EUR odds at each level of filtering, but AMR odds were significantly lower only for recurrent DUP carriers. 513 514 Unmatched odds were calculated using data from 46,869 European (EUR), 3,680 African (AFR), 515 and 7,870 admixed American (AMR) individuals. 516



517

518 Fig. 6: Odds of carrying individual recurrent CNVs for non-EUR compared to EUR ancestry

groups in SPARK. Odds were computed as the number of carriers divided by the number of
non-carriers of a given recurrent CNV. Odds ratios (ORs) were computed as AFR odds divided
by EUR odds (purple dots) or AMR odds divided by EUR odds (blue dots) using unmatched
(open dots) or matched (filled dots) data. Error bars indicate 95% Fisher confidence limits for
the OR computed using matched data, and the *p*-value is for the corresponding two-sided
Fisher's exact test for that OR. The red dashed lines indicate the expected OR of 1 (i.e., equal

odds). The purple half circle corresponds to an OR of zero; this recurrent CNV was not

- observed in the AFR ancestry group. Unmatched odds were calculated using data from 46,869
- 527 European (EUR), 3,680 African (AFR), and 7,870 admixed American (AMR) individuals.

528

- 529
- 530
- 531 532
- 55Z









Extended Data Fig. 1: Genetic ancestry and self-identified ethnicity of UK Biobank CNV study
 participants. a. The first two ancestry principal components (PCs) are plotted with colors

indicating inferred genetic ancestry. The subset of European (EUR)-ancestry individuals with
 self-declared white British (WB) ethnicity as defined by Data-Field 22006 is also shown. b.

542 Genetic ancestry was called when the posterior probability was at least 0.65, but 93.2% of the

- calls were made with posterior probability \geq 0.9. **c.** Self-declared ethnicity varied within the
- 544 EUR, South Asian (SAS), and African (AFR) genetic ancestry groups; 100% of the individuals
- 545 included in the WB subset of the EUR-ancestry group identified themselves as being British.
- 546



547 548

Extended Data Fig. 2: CNV carrier prevalence in the UK Biobank by ancestry after excluding 549 550 all third-degree or closer relatives. These results are essentially the same to those obtained 551 prior to excluding relatives (compare to Fig. 1). a. When CNVs are not filtered based on 552 recurrence or burden, deletion (DEL) carrier prevalence is higher than expected for the South 553 Asian ancestry (SAS) group, and duplication (DUP) carrier prevalence is lower than expected for the African ancestry (AFR) group (χ^2 = 126.67). **b.** When considering only recurrent CNVs, 554 there were fewer AFR-ancestry DEL and DUP carriers than expected (χ^2 = 42.07). c. Filtering 555 556 instead on burden (total $1/LOEUF \ge 5.7$), there were fewer DEL and DUP carriers than expected for both the AFR and SAS groups (χ^2 = 108.76). c. Limiting to carriers of recurrent CNVs with 557 558 total $1/\text{LOEUF} \ge 5.7$, DEL carrier prevalence was lower than expected for both AFR and SAS, but 559 DUP carrier prevalence was only lower than expected for AFR ($\chi^2 = 50.43$). Plus signs indicate significantly higher than expected carrier prevalence, and minus signs indicate significantly 560 lower than expected carrier prevalence. Ancestry-specific carrier prevalence was computed as 561 562 the number of carriers of at least one DEL (or DUP) divided by the total number of individuals in 563 that ancestry group. Simulated p-values (2000 replicates) were less than .0005 for all four chisquare tests of independence. 1/LOEUF, inverse loss-of-function observed/expected upper-564 bound fraction; *FDR-corrected p-value < .05; **FDR-corrected p-value < .005; ***FDR-565 corrected p-value < .0005. An additional category ("Neither") that was included in each chi-566 567 square test is not shown in the bar charts. 568





572 Extended Data Fig. 3: Carrier prevalence for specific recurrent CNVs by ancestry in the UK Biobank after excluding all third-degree or closer relatives. These results are essentially the 573 574 same to those obtained prior to excluding relatives (compare to Fig. 2). There were significant 575 differences between expected and observed counts for 7 out of the 11 recurrent CNVs selected for analysis, χ^2 = 397.75, simulated *p*-value < .0005 (2000 replicates). Carrier prevalence was 576 577 calculated as the number of carriers of a given recurrent CNV divided by the total number of 578 individuals in that ancestry group. Plus and minus signs indicate that the standardized residuals 579 were statistically significantly higher or lower than zero, respectively, after FDR correction. 580 *FDR-corrected p-value < .05; **FDR-corrected p-value < .005; ***FDR-corrected p-value < .0005. An additional category ("none of the above") that was included in the chi-square test is 581 582 not shown in the bar chart. 583



⁵⁸⁵ 586

587 Extended Data Fig. 4: Birth locations of UK Biobank recurrent CNV carriers and non-carriers.

- 588 Overall, similar proportions of recurrent CNV carriers (**a**) and non-carriers (**b**) were born in
- 589 either the UK or the Republic of Ireland. (c) A Mantel-Haenszel test of homogeneity indicated
- the birth location odds ratios (ORs) were stratified by ancestry ($\chi^2 = 12.641$, p = .005).
- 591 Ancestry-specific ORs suggest that WB recurrent CNV carriers are less likely (OR = 0.880,
- 592 Fisher's exact test p < .05) whereas EUR recurrent CNV carriers are more likely (OR = 1.13,
- 593 Fisher's exact test p < .05) to have been born in the UK or Ireland than elsewhere; the birth-
- location ORs for the AFR and SAS ancestry groups did not significantly differ from 1. The
- 595 Mantel-Haenszel (M-H) pooled OR also did not significantly differ from 1. Note that 11 White
- 596 British (WB), 7 other European (EUR), 2 South Asian (SAS), and 0 African (AFR) recurrent CNV
- 597 carriers were missing birth location data; no non-carriers were missing this data. Odds were
- calculated as the number of recurrent CNV carriers divided by the number of non-carriers. Error
- bars show 95% Wald confidence limits for the ORs.
- 600





603 **Extended Data Fig. 5: UK Biobank propensity-score matching protocol. a.** 1:1 nearest-604 neighbor matching was performed after excluding subjects who were missing age and/or 605 Townsend deprivation index (TDI) data. Two WB subsamples were matched to the filtered AFR 606 sample (*n* = 8,425) and the filtered SAS sample (*n* = 8,848) based on TDI, age, and sex. The 607 overlap between the density plots for TDI (top) and age (bottom) was dramatically improved

between (**b**) the AFR and WB samples and (**c**) the SAS and WB samples after matching.

609



610 611

Extended Data Fig. 6: Genetic ancestry of SPARK CNV study participants. a. The first two
 ancestry principal components (PCs) are plotted with colors indicating inferred genetic
 ancestry. b. Genetic ancestry was called when the posterior probability was at least 0.65, but

615 96.8% of the European (EUR), 83.3% of African (AFR), and 79.4% of admixed American (AMR)

- 616 ancestry calls were made with posterior probability ≥ 0.9 .
- 617



618



EUR 🔲 AFR

EUR AMR

- 625 dramatically improved between (**b**) the AFR and EUR samples and (**c**) the AMR and EUR samples 626 after matching.
- 627
- 628

629 630	Literature Cited		
631 632	1.	Pös, O. <i>et al.</i> DNA copy number variation: Main characteristics, evolutionary significance, and pathological aspects. <i>Biomedical Journal</i> 44 , 548-559 (2021).	
633 634 635	2.	Kendall, K.M. <i>et al.</i> Cognitive performance and functional outcomes of carriers of pathogenic copy number variants: Analysis of the UK Biobank. <i>The British Journal of Psychiatry</i> 214 , 297-304 (2019).	
636 637 638	3.	Alexander-Bloch, A. <i>et al.</i> Copy number variant risk scores associated with cognition, psychopathology, and brain structure in youths in the Philadelphia Neurodevelopmental Cohort. <i>JAMA Psychiatry</i> (2022).	
639 640 641	4.	Mollon, J., Almasy, L., Jacquemont, S. & Glahn, D.C. The contribution of copy number variants to psychiatric symptoms and cognitive ability. <i>Molecular Psychiatry</i> 28 , 1480-1493 (2023).	
642 643	5.	Owen, D. <i>et al.</i> Effects of pathogenic CNVs on physical traits in participants of the UK Biobank. <i>BMC Genomics</i> 19 , 867 (2018).	
644 645	6.	Hujoel, M.L.A. <i>et al.</i> Influences of rare copy-number variation on human complex traits. <i>Cell</i> 185 , 4233-4248.e27 (2022).	
646 647	7.	Auwerx, C. <i>et al.</i> The individual and global impact of copy-number variants on complex human traits. <i>The American Journal of Human Genetics</i> 109 , 647-668 (2022).	
648 649	8.	Crawford, K. <i>et al.</i> Medical consequences of pathogenic CNVs in adults: Analysis of the UK Biobank. <i>Journal of Medical Genetics</i> 56 , 131 (2019).	
650 651	9.	Aguirre, M., Rivas, M.A. & Priest, J. Phenome-wide burden of copy-number variation in the UK Biobank. <i>Am J Hum Genet</i> 105 , 373-383 (2019).	
652 653	10.	Collins, R.L. <i>et al.</i> A cross-disorder dosage sensitivity map of the human genome. <i>Cell</i> 185 , 3041-3055.e25 (2022).	
654 655	11.	Auwerx, C. <i>et al.</i> Rare copy-number variants as modulators of common disease susceptibility. <i>Genome Medicine</i> 16 , 5 (2024).	
656 657 658	12.	Merikangas, A.K., Corvin, A.P. & Gallagher, L. Copy-number variants in neurodevelopmental disorders: Promises and challenges. <i>Trends in Genetics</i> 25 , 536-544 (2009).	
659 660	13.	Coe, B.P. <i>et al.</i> Refining analyses of copy number variation identifies specific genes associated with developmental delay. <i>Nature Genetics</i> 46 , 1063-1071 (2014).	

661 662 663	14.	Birnbaum, R., Mahjani, B., Loos, R.J.F. & Sharp, A.J. Clinical characterization of copy number variants associated with neurodevelopmental disorders in a large-scale multiancestry biobank. <i>JAMA Psychiatry</i> 79 , 250-259 (2022).
664 665 666	15.	Zarrei, M. <i>et al.</i> Gene copy number variation and pediatric mental health/neurodevelopment in a general population. <i>Human Molecular Genetics</i> 32 , 2411-2421 (2023).
667 668	16.	Malhotra, D. & Sebat, J. CNVs: Harbingers of a rare variant revolution in psychiatric genetics. <i>Cell</i> 148 , 1223-1241 (2012).
669 670	17.	Calle Sánchez, X. <i>et al.</i> Comparing copy number variations in a Danish case cohort of individuals with psychiatric disorders. <i>JAMA Psychiatry</i> 79 , 59-69 (2022).
671 672	18.	Rees, E. & Kirov, G. Copy number variation and neuropsychiatric illness. <i>Current Opinion in Genetics & Development</i> 68, 57-63 (2021).
673 674	19.	Sebat, J. <i>et al.</i> Strong association of de novo copy number mutations with autism. <i>Science</i> 316 , 445-449 (2007).
675 676 677	20.	Leppa, Virpi M. <i>et al.</i> Rare inherited and de novo CNVs reveal complex contributions to ASD risk in multiplex families. <i>The American Journal of Human Genetics</i> 99 , 540-554 (2016).
678 679	21.	Fu, J.M. <i>et al.</i> Rare coding variation provides insight into the genetic architecture and phenotypic context of autism. <i>Nature Genetics</i> 54 , 1320-1331 (2022).
680 681	22.	Vicari, S. <i>et al.</i> Copy number variants in autism spectrum disorders. <i>Progress in Neuro-</i> <i>Psychopharmacology and Biological Psychiatry</i> 92 , 421-427 (2019).
682 683	23.	Marshall, C.R. <i>et al.</i> Contribution of copy number variants to schizophrenia from a genome-wide study of 41,321 subjects. <i>Nature Genetics</i> 49 , 27-35 (2017).
684 685 686	24.	Bassett, A.S., Scherer, S.W. & Brzustowicz, L.M. Copy number variations in schizophrenia: Critical review and new perspectives on concepts of genetics and disease. <i>American Journal of Psychiatry</i> 167 , 899-914 (2010).
687 688	25.	Maury, E.A. <i>et al.</i> Schizophrenia-associated somatic copy-number variants from 12,834 cases reveal recurrent NRXN1 and ABCB11 disruptions. <i>Cell Genomics</i> 3 , 100356 (2023).
689 690	26.	McElroy, J.P., Nelson, M.R., Caillier, S.J. & Oksenberg, J.R. Copy number variation in African Americans. <i>BMC Genetics</i> 10 , 15 (2009).
691 692	27.	Nyangiri, O.A. <i>et al.</i> Copy number variation in human genomes from three major ethno- linguistic groups in Africa. <i>BMC Genomics</i> 21 , 289-289 (2020).

693	28.	Wineinger, N.E. et al. Characterization of autosomal copy-number variation in African
694		Americans: The HyperGEN study. <i>European Journal of Human Genetics</i> 19 , 1271-1275
695		(2011).

- Yilmaz, F. *et al.* Genome-wide copy number variations in a large cohort of Bantu African
 children. *BMC Medical Genomics* 14, 129 (2021).
- Gautam, P. *et al.* Spectrum of large copy number variations in 26 diverse Indian
 populations: Potential involvement in phenotypic diversity. *Human Genetics* 131, 131143 (2012).
- Gao, Y. *et al.* A pangenome reference of 36 Chinese populations. *Nature* 619, 112-121
 (2023).
- 32. Sánchez, S. *et al.* Frequent copy number variants in a cohort of Mexican-Mestizo
 individuals. *Molecular Cytogenetics* 16, 2 (2023).
- Redon, R. *et al.* Global variation in copy number in the human genome. *Nature* 444, 444454 (2006).
- Wong, K.K. *et al.* A comprehensive analysis of common copy-number variations in the
 human genome. *The American Journal of Human Genetics* **80**, 91-104 (2007).
- Armengol, L. *et al.* Identification of copy number variants defining genomic differences
 among major human groups. *PLOS ONE* 4, e7230 (2009).
- 71136.Itsara, A. et al. Population analysis of large copy number variants and hotspots of human712genetic disease. The American Journal of Human Genetics 84, 148-161 (2009).
- 71337.Sudmant, P.H. *et al.* Global diversity, population stratification, and selection of human714copy-number variation. *Science* **349**, aab3761 (2015).
- Sudmant, P.H. *et al.* An integrated map of structural variation in 2,504 human genomes. *Nature* 526, 75-81 (2015).
- 717 39. Collins, R.L. *et al.* A structural variation reference for medical and population genetics.
 718 *Nature* 581, 444-451 (2020).
- 40. Ebert, P. *et al.* Haplotype-resolved diverse human genomes and integrated analysis of
 structural variation. *Science* **372**, eabf7117 (2021).
- 41. Bamshad, M., Wooding, S., Salisbury, B.A. & Stephens, J.C. Deconstructing the
 relationship between genetics and race. *Nature Reviews Genetics* 5, 598-609 (2004).
- 42. Edwards, A.W.F. Human genetic diversity: Lewontin's fallacy. *BioEssays* 25, 798-801
 (2003).

- 43. Sirugo, G., Williams, S.M. & Tishkoff, S.A. The missing diversity in human genetic studies. *Cell* **177**, 26-31 (2019).
- 44. Szpiech, Z.A. *et al.* Ancestry-dependent enrichment of deleterious homozygotes in runs
 of homozygosity. *The American Journal of Human Genetics* **105**, 747-762 (2019).
- 45. Esoh, K. & Wonkam, A. Evolutionary history of sickle-cell mutation: Implications for
 global genetic medicine. *Human Molecular Genetics* **30**, R119-R128 (2021).
- 46. Daneshpajouhnejad, P., Kopp, J.B., Winkler, C.A. & Rosenberg, A.Z. The evolving story of
 apolipoprotein L1 nephropathy: The end of the beginning. *Nature Reviews Nephrology*18, 307-320 (2022).
- A7. Nédélec, Y. *et al.* Genetic ancestry and natural selection drive population differences in
 immune responses to pathogens. *Cell* **167**, 657-669.e21 (2016).
- Randolph, H.E. *et al.* Genetic ancestry effects on the response to viral infection are
 pervasive but cell type specific. *Science* **374**, 1127-1133 (2021).
- Yang, H.-C., Chen, C.-W., Lin, Y.-T. & Chu, S.-K. Genetic ancestry plays a central role in
 population pharmacogenomics. *Communications Biology* 4, 171 (2021).
- 740 50. Corpas, M. *et al.* Addressing ancestry and sex bias in pharmacogenomics. *Annual Review*741 *of Pharmacology and Toxicology* (2023).
- 51. Karczewski, K.J. *et al.* The mutational constraint spectrum quantified from variation in
 141,456 humans. *Nature* 581, 434-443 (2020).
- 52. Schrider, D.R. & Hahn, M.W. Gene copy-number polymorphism in nature. *Proc Biol Sci*277, 3213-21 (2010).
- 746 53. Porubsky, D. *et al.* Recurrent inversion polymorphisms in humans associate with genetic
 747 instability and genomic disorders. *Cell* 185, 1986-2005.e26 (2022).
- 54. Gouveia, M.H. *et al.* Unappreciated subcontinental admixture in europeans and
 european americans and implications for genetic epidemiology studies. *Nature Communications* 14, 6802 (2023).
- Auton, A. *et al.* A global reference for human genetic variation. *Nature* 526, 68-74 (2015).
- 753 56. Bick, A.G. *et al.* Genomic data in the All of Us research program. *Nature* (2024).

754 57. Hayeck, T.J. *et al.* Ancestry adjustment improves genome-wide estimates of regional
755 intolerance. *Genetics* 221, iyac050 (2022).

- 58. Lewis, A.C.F. *et al.* Getting genetic ancestry right for science and society. *Science* 376,
 250-252 (2022).
- National Academies of Sciences, Engineering, & Medicine. Using population descriptors *in genetics and genomics research: A new framework for an evolving field*, 240 (The
 National Academies Press, Washington, DC, 2023).
- Marchini, J., Cardon, L.R., Phillips, M.S. & Donnelly, P. The effects of human population
 structure on large genetic association studies. *Nature Genetics* 36, 512-517 (2004).
- Tian, C., Gregersen, P.K. & Seldin, M.F. Accounting for ancestry: Population substructure
 and genome-wide association studies. *Human Molecular Genetics* 17, R143-R150 (2008).
- Bycroft, C. *et al.* The UK Biobank resource with deep phenotyping and genomic data. *Nature* 562, 203-209 (2018).
- Feliciano, P. *et al.* SPARK: A US cohort of 50,000 families to accelerate autism research. *Neuron* 97, 488-493 (2018).
- Wang, K. *et al.* PennCNV: An integrated hidden Markov model designed for highresolution copy number variation detection in whole-genome snp genotyping data. *Genome Res* 17, 1665-74 (2007).
- Colella, S. *et al.* Quantisnp: An objective Bayes hidden-Markov model to detect and
 accurately map copy number variation using snp genotyping data. *Nucleic Acids Res* 35,
 2013-25 (2007).
- Jean-Louis, M. Python based parallel CNV calling prioritizing mpi4py usage and memory
 optimization. in *Zenodo* (2019).
- Huguet, G. *et al.* Genome-wide analysis of gene dosage in 24,092 individuals estimates
 that 10,000 genes modulate cognitive ability. *Mol Psychiatry* 26, 2663-2676 (2021).
- Sanders, Stephan J. *et al.* Multiple recurrent de novo CNVs, including duplications of the
 7q11.23 Williams syndrome region, are strongly associated with autism. *Neuron* **70**, 863885 (2011).
- 782 69. Manichaikul, A. *et al.* Robust relationship inference in genome-wide association studies.
 783 *Bioinformatics* 26, 2867-2873 (2010).
- 784 70. Meyer, D. *et al.* Misc functions of the department of statistics, probability theory group
 785 (formerly: E1071), tu wien. 1.7-3 edn (<u>https://CRAN.R-project.org/package=e1071</u>),
 786 2020).
- 787 71. Ho, D., Imai, K., King, G. & Stuart, E.A. Matchlt: Nonparametric preprocessing for
 788 parametric causal inference. *Journal of Statistical Software* 42, 1 28 (2011).

- 789 72. R Core Team. R: A language and environment for statistical computing, (R Foundation
- 790 for Statistical Computing, Vienna, Austria, 2022).